NASDAQ:PCRX
Pacira Pharmaceuticals Stock News
$30.33
-0.130 (-0.427%)
At Close: May 31, 2024
Pacira BioSciences Q1 EPS $0.530 Beats $0.320 Estimate, Sales $105.684M Beat $102.970M Estimate
12:27pm, Thursday, 07'th May 2020Pacira BioSciences Q1 EPS $0.530 Beats $0.320 Estimate, Sales $105.700M Beat $102.970M Estimate
12:05pm, Thursday, 07'th May 2020Pacira BioSciences Reports First Quarter 2020 Financial Results and Business Update
12:00pm, Thursday, 07'th May 2020
-- Total revenues increased 16 percent over prior year first quarter ---- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., May 07, 2020 -- Pacira BioSciences, Inc..
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
12:00am, Thursday, 07'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
NovaBay Pharmaceuticals Appoints Andrew D. Jones Chief Financial Officer
12:00am, Tuesday, 05'th May 2020
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the appointment of Andrew D. Jones as Chief Financial Officer and Treasurer, effective M
Pacira BioSciences Appoints Donald C. Manning, M.D., Ph.D. as Chief Medical Officer
11:30am, Monday, 04'th May 2020
Pacira BioSciences, Inc. (PCRX), a leading provider of innovative non-opioid pain management options, today announces the appointment of Donald C. Manning, M.D., Ph.D., as the Company’s Chief Medica
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
Q1 2020 Earnings Estimate for Pacira Biosciences Inc Issued By Wedbush (NASDAQ:PCRX)
05:14am, Friday, 01'st May 2020
Pacira Biosciences Inc (NASDAQ:PCRX) – Equities researchers at Wedbush cut their Q1 2020 earnings per share (EPS) estimates for Pacira Biosciences in a research note issued to investors on Monday, A
Viking Therapeutics (VKTX) Gets a Buy Rating from Stifel Nicolaus
12:26am, Friday, 01'st May 2020
In a report released yesterday, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Viking Therapeutics (VKTX), with a price target of $14.00.
Viking Therapeutics (VKTX) Gets a Buy Rating from Stifel Nicolaus
12:26am, Friday, 01'st May 2020
In a report released yesterday,
Derek Archila
from Stifel Nicolaus reiterated a
Buy
rating on Viking Therapeutics (
VKTX
–
Research Report
), with a price target of
$14.00
. The company’s shares c
Pacira (PCRX) to Report Q1 Results: Wall Street Expects Earnings Growth
04:34pm, Thursday, 30'th Apr 2020
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stifel Nicolaus Remains a Hold on Amarin (AMRN)
04:07pm, Thursday, 30'th Apr 2020
In a report released today, Derek Archila from Stifel Nicolaus reiterated a Hold rating on Amarin (AMRN), with a price target of $8.00. The company's
Stifel Nicolaus Remains a Hold on Amarin (AMRN)
04:07pm, Thursday, 30'th Apr 2020
In a report released today,
Derek Archila
from Stifel Nicolaus reiterated a
Hold
rating on Amarin (
AMRN
–
Research Report
), with a price target of
$8.00
. The company’s shares closed last Thursd
PCRX or CTLT: Which Is the Better Value Stock Right Now?
03:40pm, Thursday, 30'th Apr 2020
PCRX vs. CTLT: Which Stock Is the Better Value Option?
Pacira to Report First Quarter 2020 Financial Results on Thursday May 7, 2020
11:30am, Thursday, 30'th Apr 2020
Pacira BioSciences, Inc. (PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Thursday, May 7, 2020. International callers may dial 1-
